1. |
Ammendola M, Leporini C, Marech I, et al. Targeting mast cells tryptase in tumor microenvironment:a potential antiangiogenetic strategy. Biomed Res Int, 2014, 2014:154702.
|
2. |
Chang LH, Pan SL, Lai CY, et al. Activated PAR-2 regulates pancreatic cancer progression through ILK/HIF-α-induced TGF-αexpression and MEK/VEGF-A-mediated angiogenesis. Am J Pathol, 2013, 183(2):566-575.
|
3. |
Carneiro-Lobo TC, Lima MT, Mariano-Oliveira A, et al. Expression of tissue factor signaling pathway elements correlates with the production of vascular endothelial growth factor and interleukin-8 in human astrocytoma patients. Oncol Rep, 2014, 31(2):679-686.
|
4. |
Wang Y, Lin M, Weng H, et al. ENMD-1068, a protease-activated receptor 2 antagonist, inhibits the development of endometriosis in a mouse model. Am J Obstet Gynecol, 2014, 210(6):531.e1-531.e8.
|
5. |
Rasmussen JG, Riis SE, Frøbert O, et al. Activation of protease-activated receptor 2 induces VEGF independently of HIF-1. PLoS One, 2012, 7(9):e46087.
|
6. |
Sedda S, Marafini I, Caruso R, et al. Proteinase activated-receptorsassociated signaling in the control of gastric cancer. World J Gastroenterol, 2014, 20(34):11977-11984.
|
7. |
Wang GJ, Wang YB, Li DN, et al. Expression of protease-activated receptor-2 in human gastric stromal tumor and its clinicopathological significance. Hepatogastroenterology, 2013, 60(128):2125-2128.
|
8. |
Ossovskaya VS, Bunnett NW. Protease-activated receptors:contribution to physiology and disease. Physiol Rev, 2004, 84(2):579-621.
|
9. |
Iablokov V, Hirota CL, Peplowski MA, et al. Proteinase-activated receptor 2 (PAR2) decreases apoptosis in colonic epithelial cells. J Biol Chem, 2014, 289(49):34366-34377.
|
10. |
Maeda S, Ohno K, Uchida K, et al. Intestinal protease-activated receptor-2 and fecal serine protease activity are increased in canine inflammatory bowel disease and may contribute to intestinal cytokine expression. J Vet Med Sci, 2014, 76(8):1119-1127.
|
11. |
Fujimoto D, Hirono Y, Goi T, et al. Expression of protease activated receptor-2 (PAR-2) in gastric cancer. J Surg Oncol, 2006, 93(2):139-144.
|
12. |
Jahan I, Fujimoto J, Alam SM, et al. Role of protease activated receptor-2 in tumor advancement of ovarian cancers. Ann Oncol, 2007, 18(9):1506-1512.
|
13. |
Caruso R, Pallone F, Fina D, et al. Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. Am J Pathol, 2006, 169(1):268-278.
|
14. |
Darmoul D, Gratio V, Devaud H, et al. Protease-activated receptor 2 in colon cancer:trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem, 2004, 279(20):20927-20934.
|
15. |
Hirota CL, Moreau F, Iablokov V, et al. Epidermal growth factor receptor transactivation is required for proteinase-activated receptor-2-induced COX-2 expression in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol, 2012, 303(1):G111-G119.
|
16. |
van der Merwe JQ, Hollenberg MD, MacNaughton WK. EGF receptor transactivation and MAP kinase mediate proteinase-activated receptor-2-induced chloride secretion in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol, 2008, 294(2):G441-G451.
|
17. |
Michel N, Heuzé-Vourc'h N, Lavergne E, et al. Growth and survival of lung cancer cells:regulation by kallikrein-related peptidase 6 via activation of proteinase-activated receptor 2 and the epidermal growth factor receptor. Biol Chem, 2014, 395(9):1015-1025.
|
18. |
Shimamoto R, Sawada T, Uchima Y, et al. A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. Int J Oncol, 2004, 24(6):1401-1406.
|
19. |
Syeda F, Grosjean J, Houliston RA, et al. Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways. J Biol Chem, 2006, 281(17):11792-11804.
|
20. |
Kawaguchi M, Kanemaru A, Sawaguchi A, et al. Hepatocyte growth factor activator inhibitor type 1 maintains the assembly of keratin into desmosomes in keratinocytes by regulating protease-activated receptor 2-dependent p38 signaling. Am J Pathol, 2015, [Epub ahead of print].
|
21. |
Defea KA, Zalevsky J, Thoma MS, et al. Beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol, 2000, 148(6):1267-1281.
|
22. |
Xiao YQ, Malcolm K, Worthen GS, et al. Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta. J Biol Chem, 2002, 277(17):14884-14893.
|
23. |
Fyfe M, Bergström M, Aspengren S, et al. PAR-2 activation in intestinal epithelial cells potentiates interleukin-1beta-induced chemokine secretion via MAP kinase signaling pathways. Cytokine, 2005, 31(5):358-367.
|